These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 7368384)
21. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. Badawi AF; Stern SJ; Lang NP; Kadlubar FF Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986 [TBL] [Abstract][Full Text] [Related]
22. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381 [TBL] [Abstract][Full Text] [Related]
23. The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer. Giannakopoulos X; Charalabopoulos K; Baltogiannis D; Chatzikiriakidou A; Alamanos Y; Georgiou I; Evangelou A; Agnantis N; Sofikitis N Anticancer Res; 2002; 22(6B):3801-4. PubMed ID: 12552997 [TBL] [Abstract][Full Text] [Related]
24. N-acetyltransferase activity is involved in paclitaxel-induced N-acetylation of 2-aminofluorene in human bladder cancer cells (T24). Yang CC; Yang JH; Lu HF; Chen SY; Lin SY; Chung JG Anticancer Res; 2004; 24(3a):1501-6. PubMed ID: 15274316 [TBL] [Abstract][Full Text] [Related]
25. Overrepresentation of the slow acetylator phenotype in painters suffering from urinary bladder cancer. Golka K; Kempkes M; Flieger A; Blaszkewicz M; Bolt HM Med Lav; 1997; 88(5):425-6. PubMed ID: 9489306 [No Abstract] [Full Text] [Related]
26. [HER-2 and TOP2A gene amplification in urinary bladder cancer]. Simon R; Atefy R; Wagner U; Forster T; Fijan A; Bruderer J; Wilber K; Mihatsch M; Gasser T G; Sauter G Verh Dtsch Ges Pathol; 2002; 86():176-83. PubMed ID: 12691100 [No Abstract] [Full Text] [Related]
27. The inhibition of N-acetyltransferase activity and gene expression in human bladder cancer cells (T24) by shikonin. Yeh CC; Wu LT; Lin SY; Li TM; Chung JG In Vivo; 2004; 18(1):21-31. PubMed ID: 15011747 [TBL] [Abstract][Full Text] [Related]
28. The molecular mechanism underlying Roberts syndrome involves loss of ESCO2 acetyltransferase activity. Gordillo M; Vega H; Trainer AH; Hou F; Sakai N; Luque R; Kayserili H; Basaran S; Skovby F; Hennekam RC; Uzielli ML; Schnur RE; Manouvrier S; Chang S; Blair E; Hurst JA; Forzano F; Meins M; Simola KO; Raas-Rothschild A; Schultz RA; McDaniel LD; Ozono K; Inui K; Zou H; Jabs EW Hum Mol Genet; 2008 Jul; 17(14):2172-80. PubMed ID: 18411254 [TBL] [Abstract][Full Text] [Related]
29. Luteolin induces N-acetylation and DNA adduct of 2-aminofluorene accompanying N-acetyltransferase activity and gene expression in human bladder cancer T24 cell line. Su CC; Chen GW; Yeh CC; Yang MD; Hung CF; Chung JG Anticancer Res; 2003; 23(1A):355-62. PubMed ID: 12680237 [TBL] [Abstract][Full Text] [Related]
30. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer. Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680 [TBL] [Abstract][Full Text] [Related]
31. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine. Filiadis IF; Georgiou IA; Giannakopoulos X Br J Urol; 1998 Feb; 81(2):342-3. PubMed ID: 9488096 [No Abstract] [Full Text] [Related]
32. Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). De Leon JH; Martell KJ; Vatsis KP; Weber WW Drug Metab Dispos; 1995 Dec; 23(12):1354-61. PubMed ID: 8689943 [TBL] [Abstract][Full Text] [Related]
33. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Brockmöller J; Kerb R; Drakoulis N; Staffeldt B; Roots I Cancer Res; 1994 Aug; 54(15):4103-11. PubMed ID: 8033143 [TBL] [Abstract][Full Text] [Related]
34. Use of puromycin N-acetyltransferase (PAC) as a new reporter gene in transgenic animals. Gómez Lahoz E; López de Haro MS; Nieto A; Esponda P Nucleic Acids Res; 1991 Jun; 19(12):3465. PubMed ID: 2062668 [No Abstract] [Full Text] [Related]
35. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Wolf H; Lower GM; Bryan GT Scand J Urol Nephrol; 1980; 14(2):161-5. PubMed ID: 7209420 [TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism and cancer susceptibility: evidence concerning acetyltransferases and cancer of the urinary bladder. Hein DW Bioessays; 1988 Dec; 9(6):200-4. PubMed ID: 3072000 [No Abstract] [Full Text] [Related]
37. Genetic regulation of N-acetyltransferase in target organs of arylamine tumors: homologous expression in human and hamster bladder and colon. Hein DW Proc West Pharmacol Soc; 1991; 34():55-60. PubMed ID: 1788341 [No Abstract] [Full Text] [Related]
38. The biochemical indices of genetic susceptibility to cancer. Acetylation phenotype and bladder cancer. Hanke J; Krajewska B Pol J Occup Med; 1988; 1(4):306-11. PubMed ID: 2979565 [No Abstract] [Full Text] [Related]
39. [Significance of N-acetyltransferase phenotype in development of bladder neoplasms]. Wolf H; Lower GM; Bryan GT Ugeskr Laeger; 1980 Feb; 142(6):382-5. PubMed ID: 7368384 [No Abstract] [Full Text] [Related]